Evidence map›Paper›PMID 35659421›Full record

ArticleMedicina clinica2022

Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.

Haitham M H Qutob, Ramadan A Saad, Hamza Bali, Abdulaziz Osailan, Jumana Jaber, Emad Alzahrani, Jamilah Alyami, Hani Elsayed, Raed Alserihi, Osama A Shaikhomar

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina clinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Haitham M H QutobDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabigh, 25732, Saudi Arabia; Medical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia. Electronic address: hqutob@yahoo.com.
Ramadan A SaadMedical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia; Physiology Department, Faculty of Medicine, Ainshams University, Cairo, Egypt.
Hamza BaliInternal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Abdulaziz OsailanInternal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Jumana JaberInternal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Emad AlzahraniInternal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Jamilah AlyamiInternal Medicine Department, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Hani ElsayedMedical Laboratory Sciences Department, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia; Physics Department, Faculty of Science, Mansoura University, Mansoura, Egypt.
Raed AlserihiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 3D Bioprinting Unit, Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Osama A ShaikhomarDepartment of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Soliman Fakeeh Hospital · SAKing Abdulaziz University · SAMansoura University · EGUmm al-Qura University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers. MATERIALS AND

methodsThis study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab.

resultsThe WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 (p=0.004 and p=0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with p=0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant (p=0.002).

conclusionThe study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.

Indexed as

COVID-19Chronic DiseaseDexamethasoneHumansRetrospective StudiesTreatment OutcomeDexamethasoneCOVID-19CRPDexametasonaDexamethasoneLeucocitosLinfocitosLymphocytesNeutrófilosNeutrophilsTocilizumabWBCs

Identifiers

PMID35659421
PMCPMC9035366
OpenAlexW4224321207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.